Stocks to Watch: LLY, TRIP, CRM & More
Senior Producer, CNBC
Take a look at some of Friday's morning movers:
Eli Lilly - The drugmaker said its experimental Alzheimer's drug did not meet its primary endpoints in a study, but said it did slow cognitive decline in some patients and that studies will continue. It calls the latter development "encouraging."
TripAdvisor - The travel services company's stock has been upgraded to "buy" from "neutral" at Citi. The firm said a recent pullback in the shares has created an "interesting valuation entry point."
Salesforce.com - The company earned $0.42 per share for the second quarter, excluding certain items, three cents above estimates. The business software producer projected third-quarter earnings per share of $0.31 to $0.32 per share, below estimates of $0.34, but also raised its full-year view to $1.48 to $1.51 per share from the prior $1.45 to $1.49. (Read More: Salesforce Earnings Head for the Clouds.)
Autodesk - Autodesk reported second-quarter profit of $0.48 per share, below analysts' estimates of $0.49. It also lowered its full-year revenue forecast, predicting 4 percent to 6 percent growth versus a previous estimate of 10 percent. The software maker’s current quarter outlook is $0.40 to $0.45 per share, below estimates of $0.50. The company cited execution challenges, as well as an uneven global economy.
General Growth Properties - UBS is downgrading the mall operator's stock to "neutral" from "buy," saying it's trading near its price target and that the chance of a buyout by rivals like Simon Property Group is small. (Read More: Ackman Calls for Sale of General Growth Properties.)
Brinker International - The restaurant operator has raised its quarterly dividend to $0.20 from $0.16, an increase of 25 percent. It’s also announced an additional $500 million in share buybacks. Brinker is the parent of the Chili’s and Maggiano’s restaurant chains.
Bristol-Myers Squibb - The drug company has dropped development of a hepatitis C drug after a clinical trial patient died of heart failure. The drug was acquired by Bristol when it bought Inhibitex earlier this year for $2.5 billion.
While jury deliberations continue in the U.S. patent trial pitting Apple against Samsung, a South Korean court has ruled that the companies each infringed on some of the other’s patents, and banned certain products from both companies in South Korean stores. (Read More: Apple’s Share of China Smartphone Market Drops 50 Percent.)
Supervalu - The supermarket chain owner is reportedly shopping for potential buyers, according to Bloomberg News. The report said private-equity firm Cerberus is interested in Supervalu’s Albertson’s unit, while Amsterdam’s Koninklijke Ahold is interested in the Shoppers chain. Supervalu said last month that it was exploring various options.
Boeing - The jetmaker has reaffirmed its launch scheduled for new models of its 777 and 787 aircraft. That comes after The Seattle Times had reported a slowdown in the launches of those new models.
—By CNBC’s Peter Schacknow
Questions? Comments? Email us at firstname.lastname@example.org